Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical demonstration of NK cell redirection using a bispecific engager. We report an ORR of 92.9% and CR of 66.7% in 42 patients with a median of 7 prior therapies and show that this approach is safe and may serve as a bridge to SCT. Excited to move forward with our next generation engineered NK cells in combination with engagers and mAbs. #CancerResearch #Immunotherapy #NKcells @MDAndersonNews